Current Clinical Trials in Non-muscle Invasive Bladder Cancer

Overview

Journal Urol Oncol

Publisher Elsevier

Date 2017 Aug 6

PMID 28778250

Citations 14

Authors

Mohammad Rashid Siddiqui

Campbell Grant

Thomas Sanford

Piyush K Agarwal

Affiliations

Soon will be listed here.

Abstract

Background: The treatment options for non-muscle invasive bladder cancer (NMIBC) remain limited. Bacillus Calmette-Guerin (BCG) was the last major breakthrough in bladder cancer therapy almost 4 decades ago. There have been improvements in the understanding of immune therapies and cancer biology, leading to the development of novel agents. This has led to many clinical trials that are currently underway to find the next generation of therapies for NMIBC.

Method: We reviewed clinicaltrials.org and pubmed.gov to find the recently completed and ongoing clinical trials in NIMBC. Included in this review are clinical trials that are currently active and trials that were completed in and after 2014.

Result: Many trials with BCG-naive and BCG-unresponsive/recurrent/refractory/failure patients with NMIBC are either currently underway or have been recently completed. A wide variety of novel therapeutic agents are being investigated that range from cytotoxic agents to immunomodulatory agents to targeted molecular therapies. Other approaches include cancer vaccines, gene therapies, and chemoradiation potentiation agents. Novel drug-delivery methods are also being tested.

Conclusion: This comprehensive update of current trials provides researchers an overview of the current clinical trial landscape for patients with NMIBC.

Citing Articles

Prediction of immune and targeted drug efficacy in pain-related risk subtypes for bladder cancer patients.

Wang Y, Kong Q, Li M, Gu J, Chen J, Yang L Heliyon. 2023; 9(7):e17690.

PMID: 37455996 PMC: 10338970. DOI: 10.1016/j.heliyon.2023.e17690.

Healthcare Resource Utilization and Cost Burden of BCG-Treated Non-Muscle Invasive Bladder Cancer Patients in Germany: A Retrospective Claims Analysis.

Quignot N, Jiang H, Doobaree I, Lehmann J, Ghatnekar O Clinicoecon Outcomes Res. 2023; 15:227-237.

PMID: 37035831 PMC: 10075214. DOI: 10.2147/CEOR.S398180.

Lentiviral interferon: A novel method for gene therapy in bladder cancer.

Mokkapati S, Narayan V, Manyam G, Lim A, Duplisea J, Kokorovic A Mol Ther Oncolytics. 2022; 26:141-157.

PMID: 35847448 PMC: 9251210. DOI: 10.1016/j.omto.2022.06.005.

Extending traditional antibody therapies: Novel discoveries in immunotherapy and clinical applications.

Shin C, Kim S, Jo Y Mol Ther Oncolytics. 2021; 22:166-179.

PMID: 34514097 PMC: 8416972. DOI: 10.1016/j.omto.2021.08.005.

Nonreplicating Adenoviral Vectors: Improving Tropism and Delivery of Cancer Gene Therapy.

Tessarollo N, Domingues A, Antunes F, Dos Santos da Luz J, Rodrigues O, Cerqueira O Cancers (Basel). 2021; 13(8).

PMID: 33919679 PMC: 8069790. DOI: 10.3390/cancers13081863.

References

Kiss B, Schneider S, Thalmann G, Roth B . Is thermochemotherapy with the Synergo system a viable treatment option in patients with recurrent non-muscle-invasive bladder cancer?. Int J Urol. 2014; 22(2):158-62. DOI: 10.1111/iju.12639. View

Donin N, Chamie K, Lenis A, Pantuck A, Reddy M, Kivlin D . A phase 2 study of TMX-101, intravesical imiquimod, for the treatment of carcinoma in situ bladder cancer. Urol Oncol. 2017; 35(2):39.e1-39.e7. DOI: 10.1016/j.urolonc.2016.09.006. View

Gomes-Giacoia E, Miyake M, Goodison S, Sriharan A, Zhang G, You L . Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model; a role for cytokine production and NK cell expansion. PLoS One. 2014; 9(6):e96705. PMC: 4045574. DOI: 10.1371/journal.pone.0096705. View

Miyamoto H, Yao J, Chaux A, Zheng Y, Hsu I, Izumi K . Expression of androgen and oestrogen receptors and its prognostic significance in urothelial neoplasm of the urinary bladder. BJU Int. 2012; 109(11):1716-26. DOI: 10.1111/j.1464-410X.2011.10706.x. View

Hendricksen K, Cornel E, de Reijke T, Arentsen H, Chawla S, Witjes J . Phase 2 study of adjuvant intravesical instillations of apaziquone for high risk nonmuscle invasive bladder cancer. J Urol. 2012; 187(4):1195-9. DOI: 10.1016/j.juro.2011.11.101. View

Seager C, Puzio-Kuter A, Patel T, Jain S, Cordon-Cardo C, Mc Kiernan J . Intravesical delivery of rapamycin suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer Prev Res (Phila). 2009; 2(12):1008-14. PMC: 2789170. DOI: 10.1158/1940-6207.CAPR-09-0169. View

Rosenberg J, Hoffman-Censits J, Powles T, van der Heijden M, Balar A, Necchi A . Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016; 387(10031):1909-20. PMC: 5480242. DOI: 10.1016/S0140-6736(16)00561-4. View

Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D . Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2010; 107(6):912-8. DOI: 10.1111/j.1464-410X.2010.09654.x. View

Kawahara T, Ide H, Kashiwagi E, El-Shishtawy K, Li Y, Reis L . Enzalutamide inhibits androgen receptor-positive bladder cancer cell growth. Urol Oncol. 2016; 34(10):432.e15-23. DOI: 10.1016/j.urolonc.2016.05.016. View

10.

McKiernan J, Holder D, Ghandour R, Barlow L, Ahn J, Kates M . Phase II trial of intravesical nanoparticle albumin bound paclitaxel for the treatment of nonmuscle invasive urothelial carcinoma of the bladder after bacillus Calmette-Guérin treatment failure. J Urol. 2014; 192(6):1633-8. DOI: 10.1016/j.juro.2014.06.084. View

11.

Veeratterapillay R, Heer R, Johnson M, Persad R, Bach C . High-Risk Non-Muscle-Invasive Bladder Cancer-Therapy Options During Intravesical BCG Shortage. Curr Urol Rep. 2016; 17(9):68. PMC: 4980405. DOI: 10.1007/s11934-016-0625-z. View

12.

Lindgren D, Liedberg F, Andersson A, Chebil G, Gudjonsson S, Borg A . Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q. Oncogene. 2006; 25(18):2685-96. DOI: 10.1038/sj.onc.1209249. View

13.

Jarow J, Lerner S, Kluetz P, Liu K, Sridhara R, Bajorin D . Clinical trial design for the development of new therapies for nonmuscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop. Urology. 2013; 83(2):262-4. DOI: 10.1016/j.urology.2013.10.030. View

14.

Kamat A, Sylvester R, Bohle A, Palou J, Lamm D, Brausi M . Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol. 2016; 34(16):1935-44. PMC: 5321095. DOI: 10.1200/JCO.2015.64.4070. View

15.

Gulley J, Arlen P, Tsang K, Yokokawa J, Palena C, Poole D . Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008; 14(10):3060-9. PMC: 2673097. DOI: 10.1158/1078-0432.CCR-08-0126. View

16.

Malmstrom P, Sylvester R, Crawford D, Friedrich M, Krege S, Rintala E . An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guérin for non-muscle-invasive bladder cancer. Eur Urol. 2009; 56(2):247-56. DOI: 10.1016/j.eururo.2009.04.038. View

17.

Biot C, Rentsch C, Gsponer J, Birkhauser F, Jusforgues-Saklani H, Lemaitre F . Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer. Sci Transl Med. 2012; 4(137):137ra72. DOI: 10.1126/scitranslmed.3003586. View

18.

Dinney C, Fisher M, Navai N, ODonnell M, Cutler D, Abraham A . Phase I trial of intravesical recombinant adenovirus mediated interferon-α2b formulated in Syn3 for Bacillus Calmette-Guérin failures in nonmuscle invasive bladder cancer. J Urol. 2013; 190(3):850-6. PMC: 3951790. DOI: 10.1016/j.juro.2013.03.030. View

19.

Kaufman D, Shipley W, Feldman A . Bladder cancer. Lancet. 2009; 374(9685):239-49. DOI: 10.1016/S0140-6736(09)60491-8. View

20.

Premo C, Apolo A, Agarwal P, Citrin D . Trimodality therapy in bladder cancer: who, what, and when?. Urol Clin North Am. 2015; 42(2):169-80, vii. PMC: 4465095. DOI: 10.1016/j.ucl.2015.02.002. View